Cicletanine

Identification

Name

Cicletanine

Accession Number

DB12766

Type

Small Molecule

Groups

Investigational

Description

Cicletanine is under investigation for the treatment of Diabetes, Hypokalemia, Hyponatremia, and Arterial Hypertension.

Structure

3D

Download

MOLSDF3D-SDFPDBSMILESInChI

Similar Structures

Structure for DB12766 (Cicletanine)

×

Close

Synonyms

Not Available

Categories

• Anti-Arrhythmia Agents
• Antihypertensive Agents
• Cardiovascular Agents
• Cardiovascular System
• Diuretics
• Low-Ceiling Diuretics, Excl. Thiazides
• Natriuretic Agents

UNII

CHG7QC509W

CAS number

89943-82-8

Weight

Average: 261.71
Monoisotopic: 261.0556563

Chemical Formula

C₁₄H₁₂ClNO₂

InChI Key

CVKNDPRBJVBDSS-UHFFFAOYSA-N

InChI

InChI=1S/C14H12ClNO2/c1-8-13(17)12-7-18-14(11(12)6-16-8)9-2-4-10(15)5-3-9/h2-6,14,17H,7H2,1H3

IUPAC Name

3-(4-chlorophenyl)-6-methyl-1H,3H-furo[3,4-c]pyridin-7-ol

SMILES

CC1=C(O)C2=C(C=N1)C(OC2)C1=CC=C(Cl)C=C1

Pharmacology

Indication

Not Available

Structured Indications

Not Available

Pharmacodynamics

Not Available

Mechanism of action

Not Available

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Not Available

Route of elimination

Not Available

Half life

Not Available

Clearance

Not Available

Toxicity

Not Available

Affected organisms

Not Available

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction	Drug group
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline	7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Cicletanine.	Experimental
Acebutolol	Acebutolol may increase the hypotensive activities of Cicletanine.	Approved
Alfentanil	The risk or severity of adverse effects can be increased when Alfentanil is combined with Cicletanine.	Approved, Illicit
Alfuzosin	Alfuzosin may increase the hypotensive activities of Cicletanine.	Approved, Investigational
Aliskiren	Aliskiren may increase the hypotensive activities of Cicletanine.	Approved, Investigational
Alphacetylmethadol	The risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Cicletanine.	Experimental, Illicit
Alphaprodine	The risk or severity of adverse effects can be increased when Alphaprodine is combined with Cicletanine.	Illicit
Alprenolol	Alprenolol may increase the hypotensive activities of Cicletanine.	Approved, Withdrawn
Ambrisentan	Cicletanine may increase the hypotensive activities of Ambrisentan.	Approved, Investigational
Amifostine	Cicletanine may increase the hypotensive activities of Amifostine.	Approved, Investigational
Amlodipine	Amlodipine may increase the hypotensive activities of Cicletanine.	Approved
Atenolol	Atenolol may increase the hypotensive activities of Cicletanine.	Approved
Benazepril	Benazepril may increase the hypotensive activities of Cicletanine.	Approved, Investigational
Bendroflumethiazide	Bendroflumethiazide may increase the hypotensive activities of Cicletanine.	Approved
Benmoxin	Benmoxin may increase the hypotensive activities of Cicletanine.	Withdrawn
Bepridil	Bepridil may increase the hypotensive activities of Cicletanine.	Approved, Withdrawn
Betaxolol	Betaxolol may increase the hypotensive activities of Cicletanine.	Approved
Bethanidine	Bethanidine may increase the hypotensive activities of Cicletanine.	Approved
Bezitramide	The risk or severity of adverse effects can be increased when Bezitramide is combined with Cicletanine.	Experimental, Illicit, Withdrawn
Bietaserpine	Bietaserpine may increase the hypotensive activities of Cicletanine.	Experimental
Bimatoprost	Bimatoprost may increase the hypotensive activities of Cicletanine.	Approved, Investigational
Bisoprolol	Bisoprolol may increase the hypotensive activities of Cicletanine.	Approved
Bosentan	Bosentan may increase the hypotensive activities of Cicletanine.	Approved, Investigational
BQ-123	BQ-123 may increase the hypotensive activities of Cicletanine.	Investigational
Bretylium	Bretylium may increase the hypotensive activities of Cicletanine.	Approved
Brimonidine	Brimonidine may increase the antihypertensive activities of Cicletanine.	Approved
Brofaromine	Brofaromine may increase the hypotensive activities of Cicletanine.	Experimental
Bupranolol	Bupranolol may increase the hypotensive activities of Cicletanine.	Approved
Buprenorphine	The risk or severity of adverse effects can be increased when Buprenorphine is combined with Cicletanine.	Approved, Illicit, Investigational, Vet Approved
Butorphanol	The risk or severity of adverse effects can be increased when Butorphanol is combined with Cicletanine.	Approved, Illicit, Vet Approved
Cadralazine	Cadralazine may increase the hypotensive activities of Cicletanine.	Experimental
Cafedrine	Cicletanine may increase the hypotensive activities of Cafedrine.	Investigational
Candesartan cilexetil	Candesartan may increase the hypotensive activities of Cicletanine.	Approved
Candoxatril	Candoxatril may increase the hypotensive activities of Cicletanine.	Experimental
Captopril	Captopril may increase the hypotensive activities of Cicletanine.	Approved
Carfentanil	The risk or severity of adverse effects can be increased when Carfentanil is combined with Cicletanine.	Illicit, Vet Approved
Caroxazone	Caroxazone may increase the hypotensive activities of Cicletanine.	Withdrawn
Carteolol	Carteolol may increase the hypotensive activities of Cicletanine.	Approved
Carvedilol	Carvedilol may increase the hypotensive activities of Cicletanine.	Approved, Investigational
Celiprolol	Celiprolol may increase the hypotensive activities of Cicletanine.	Approved, Investigational
Chlorothiazide	Chlorothiazide may increase the hypotensive activities of Cicletanine.	Approved, Vet Approved
Chlorthalidone	Chlorthalidone may increase the hypotensive activities of Cicletanine.	Approved
Cilazapril	Cilazapril may increase the hypotensive activities of Cicletanine.	Approved
Clonidine	Clonidine may increase the hypotensive activities of Cicletanine.	Approved
Cloranolol	Cicletanine may increase the hypotensive activities of Cloranolol.	Experimental
Codeine	The risk or severity of adverse effects can be increased when Codeine is combined with Cicletanine.	Approved, Illicit
Cryptenamine	Cryptenamine may increase the hypotensive activities of Cicletanine.	Approved
Cyclopenthiazide	Cicletanine may increase the hypotensive activities of Cyclopenthiazide.	Experimental
Cyclothiazide	Cyclothiazide may increase the hypotensive activities of Cicletanine.	Approved
Debrisoquin	Debrisoquin may increase the hypotensive activities of Cicletanine.	Approved
Delapril	Cicletanine may increase the hypotensive activities of Delapril.	Experimental
Deserpidine	Cicletanine may increase the hypotensive activities of Deserpidine.	Approved
Dextromoramide	The risk or severity of adverse effects can be increased when Dextromoramide is combined with Cicletanine.	Experimental, Illicit
Dextropropoxyphene	The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Cicletanine.	Approved, Illicit, Withdrawn
Dezocine	The risk or severity of adverse effects can be increased when Dezocine is combined with Cicletanine.	Approved
Diazoxide	Diazoxide may increase the hypotensive activities of Cicletanine.	Approved
diethylnorspermine	diethylnorspermine may increase the hypotensive activities of Cicletanine.	Investigational
Dihydralazine	Dihydralazine may increase the hypotensive activities of Cicletanine.	Investigational
Dihydrocodeine	The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Cicletanine.	Approved, Illicit
Dihydroetorphine	The risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Cicletanine.	Experimental, Illicit
Dihydromorphine	The risk or severity of adverse effects can be increased when Dihydromorphine is combined with Cicletanine.	Experimental, Illicit
Diltiazem	Diltiazem may increase the hypotensive activities of Cicletanine.	Approved
Diphenoxylate	The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Cicletanine.	Approved, Illicit
Dorzolamide	Dorzolamide may increase the hypotensive activities of Cicletanine.	Approved
Doxazosin	Doxazosin may increase the hypotensive activities of Cicletanine.	Approved
DPDPE	The risk or severity of adverse effects can be increased when DPDPE is combined with Cicletanine.	Investigational
Efonidipine	Efonidipine may increase the hypotensive activities of Cicletanine.	Approved
Enalapril	Enalapril may increase the hypotensive activities of Cicletanine.	Approved, Vet Approved
Enalaprilat	Enalaprilat may increase the hypotensive activities of Cicletanine.	Approved
Endralazine	Endralazine may increase the hypotensive activities of Cicletanine.	Experimental
Epanolol	Cicletanine may increase the hypotensive activities of Epanolol.	Experimental
Epoprostenol	Epoprostenol may increase the hypotensive activities of Cicletanine.	Approved
Eprosartan	Eprosartan may increase the hypotensive activities of Cicletanine.	Approved
Ethylmorphine	The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Cicletanine.	Approved, Illicit
Etorphine	The risk or severity of adverse effects can be increased when Etorphine is combined with Cicletanine.	Illicit, Vet Approved
Felodipine	Felodipine may increase the hypotensive activities of Cicletanine.	Approved, Investigational
Fenoldopam	Fenoldopam may increase the hypotensive activities of Cicletanine.	Approved
Fentanyl	The risk or severity of adverse effects can be increased when Fentanyl is combined with Cicletanine.	Approved, Illicit, Investigational, Vet Approved
Ferulic acid	Ferulic acid may increase the hypotensive activities of Cicletanine.	Experimental
Fosinopril	Fosinopril may increase the hypotensive activities of Cicletanine.	Approved
Furazolidone	Furazolidone may increase the hypotensive activities of Cicletanine.	Approved, Vet Approved
Guanabenz	Guanabenz may increase the hypotensive activities of Cicletanine.	Approved
Guanadrel	Guanadrel may increase the hypotensive activities of Cicletanine.	Approved
Guanazodine	Cicletanine may increase the hypotensive activities of Guanazodine.	Experimental
Guanethidine	Guanethidine may increase the hypotensive activities of Cicletanine.	Approved
Guanfacine	Guanfacine may increase the hypotensive activities of Cicletanine.	Approved, Investigational
Guanoclor	Cicletanine may increase the hypotensive activities of Guanoclor.	Experimental
Guanoxabenz	Cicletanine may increase the hypotensive activities of Guanoxabenz.	Experimental
Guanoxan	Cicletanine may increase the hypotensive activities of Guanoxan.	Experimental
Harmaline	Harmaline may increase the hypotensive activities of Cicletanine.	Experimental
Heroin	The risk or severity of adverse effects can be increased when Heroin is combined with Cicletanine.	Approved, Illicit
Hexamethonium	Hexamethonium may increase the hypotensive activities of Cicletanine.	Experimental
Hydracarbazine	Hydracarbazine may increase the hypotensive activities of Cicletanine.	Experimental
Hydralazine	Hydralazine may increase the hypotensive activities of Cicletanine.	Approved
Hydrochlorothiazide	Hydrochlorothiazide may increase the hypotensive activities of Cicletanine.	Approved, Vet Approved
Hydrocodone	The risk or severity of adverse effects can be increased when Hydrocodone is combined with Cicletanine.	Approved, Illicit
Hydroflumethiazide	Hydroflumethiazide may increase the hypotensive activities of Cicletanine.	Approved
Hydromorphone	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Cicletanine.	Approved, Illicit
Iloprost	Iloprost may increase the hypotensive activities of Cicletanine.	Approved, Investigational
Imidapril	Imidapril may increase the hypotensive activities of Cicletanine.	Investigational
Indapamide	Indapamide may increase the hypotensive activities of Cicletanine.	Approved
Indenolol	Indenolol may increase the hypotensive activities of Cicletanine.	Withdrawn
Indoramin	Indoramin may increase the hypotensive activities of Cicletanine.	Withdrawn
Iproclozide	Iproclozide may increase the hypotensive activities of Cicletanine.	Withdrawn
Iproniazid	Iproniazid may increase the hypotensive activities of Cicletanine.	Withdrawn
Irbesartan	Irbesartan may increase the hypotensive activities of Cicletanine.	Approved, Investigational
Isocarboxazid	Isocarboxazid may increase the hypotensive activities of Cicletanine.	Approved
Isradipine	Isradipine may increase the hypotensive activities of Cicletanine.	Approved
Ketanserin	Ketanserin may increase the hypotensive activities of Cicletanine.	Investigational
Ketobemidone	The risk or severity of adverse effects can be increased when Ketobemidone is combined with Cicletanine.	Approved
Labetalol	Labetalol may increase the hypotensive activities of Cicletanine.	Approved
Lacidipine	Lacidipine may increase the hypotensive activities of Cicletanine.	Approved
Latanoprost	Latanoprost may increase the hypotensive activities of Cicletanine.	Approved, Investigational
Lercanidipine	Lercanidipine may increase the hypotensive activities of Cicletanine.	Approved, Investigational
Levomethadyl Acetate	The risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Cicletanine.	Approved
Levorphanol	The risk or severity of adverse effects can be increased when Levorphanol is combined with Cicletanine.	Approved
Linsidomine	Cicletanine may increase the hypotensive activities of Linsidomine.	Experimental
Lisinopril	Lisinopril may increase the hypotensive activities of Cicletanine.	Approved, Investigational
Lofentanil	The risk or severity of adverse effects can be increased when Lofentanil is combined with Cicletanine.	Illicit
Lofexidine	Lofexidine may increase the hypotensive activities of Cicletanine.	Approved, Investigational
Losartan	Losartan may increase the hypotensive activities of Cicletanine.	Approved
Macitentan	Cicletanine may increase the hypotensive activities of Macitentan.	Approved
Manidipine	Manidipine may increase the hypotensive activities of Cicletanine.	Approved
Mebanazine	Mebanazine may increase the hypotensive activities of Cicletanine.	Withdrawn
Mecamylamine	Mecamylamine may increase the hypotensive activities of Cicletanine.	Approved
Meptazinol	The risk or severity of adverse effects can be increased when Meptazinol is combined with Cicletanine.	Experimental
Methadone	The risk or severity of adverse effects can be increased when Methadone is combined with Cicletanine.	Approved
Methadyl Acetate	The risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Cicletanine.	Approved, Illicit
Methoserpidine	Cicletanine may increase the hypotensive activities of Methoserpidine.	Experimental
Methyldopa	Methyldopa may increase the hypotensive activities of Cicletanine.	Approved
Methylene blue	Methylene blue may increase the hypotensive activities of Cicletanine.	Investigational
Methylphenidate	Methylphenidate may decrease the antihypertensive activities of Cicletanine.	Approved, Investigational
Metipranolol	Metipranolol may increase the hypotensive activities of Cicletanine.	Approved
Metolazone	Metolazone may increase the hypotensive activities of Cicletanine.	Approved
Metoprolol	Metoprolol may increase the hypotensive activities of Cicletanine.	Approved, Investigational
Metyrosine	Cicletanine may increase the hypotensive activities of Metyrosine.	Approved
Mibefradil	Mibefradil may increase the hypotensive activities of Cicletanine.	Withdrawn
Minaprine	Minaprine may increase the hypotensive activities of Cicletanine.	Approved
Minoxidil	Minoxidil may increase the hypotensive activities of Cicletanine.	Approved
Mirodenafil	Mirodenafil may increase the antihypertensive activities of Cicletanine.	Investigational
Moclobemide	Moclobemide may increase the hypotensive activities of Cicletanine.	Approved
Moexipril	Moexipril may increase the hypotensive activities of Cicletanine.	Approved
Molsidomine	Molsidomine may increase the hypotensive activities of Cicletanine.	Approved
Morphine	The risk or severity of adverse effects can be increased when Morphine is combined with Cicletanine.	Approved, Investigational
Moxonidine	Moxonidine may increase the hypotensive activities of Cicletanine.	Approved
Muzolimine	Cicletanine may increase the hypotensive activities of Muzolimine.	Experimental
Nadolol	Nadolol may increase the hypotensive activities of Cicletanine.	Approved
Naftopidil	Naftopidil may increase the hypotensive activities of Cicletanine.	Investigational
Nalbuphine	The risk or severity of adverse effects can be increased when Nalbuphine is combined with Cicletanine.	Approved
Nebivolol	Nebivolol may increase the hypotensive activities of Cicletanine.	Approved, Investigational
Nialamide	Nialamide may increase the hypotensive activities of Cicletanine.	Withdrawn
Nicardipine	Nicardipine may increase the hypotensive activities of Cicletanine.	Approved
Nicomorphine	The risk or severity of adverse effects can be increased when Nicomorphine is combined with Cicletanine.	Experimental
Nicorandil	Nicorandil may increase the hypotensive activities of Cicletanine.	Approved
Niguldipine	Niguldipine may increase the hypotensive activities of Cicletanine.	Experimental
Nilvadipine	Nilvadipine may increase the hypotensive activities of Cicletanine.	Approved
Nimodipine	Nimodipine may increase the hypotensive activities of Cicletanine.	Approved
Nisoldipine	Nisoldipine may increase the hypotensive activities of Cicletanine.	Approved
Nitrendipine	Nitrendipine may increase the hypotensive activities of Cicletanine.	Approved
Nitroprusside	Nitroprusside may increase the hypotensive activities of Cicletanine.	Approved
Normethadone	The risk or severity of adverse effects can be increased when Normethadone is combined with Cicletanine.	Approved, Illicit
Obinutuzumab	Cicletanine may increase the hypotensive activities of Obinutuzumab.	Approved
Octamoxin	Octamoxin may increase the hypotensive activities of Cicletanine.	Withdrawn
Olmesartan	Olmesartan may increase the hypotensive activities of Cicletanine.	Approved, Investigational
Omapatrilat	Omapatrilat may increase the hypotensive activities of Cicletanine.	Investigational
Opium	The risk or severity of adverse effects can be increased when Opium is combined with Cicletanine.	Approved, Illicit
Oxprenolol	Oxprenolol may increase the hypotensive activities of Cicletanine.	Approved
Oxycodone	The risk or severity of adverse effects can be increased when Oxycodone is combined with Cicletanine.	Approved, Illicit, Investigational
Oxymorphone	The risk or severity of adverse effects can be increased when Oxymorphone is combined with Cicletanine.	Approved, Investigational, Vet Approved
Pargyline	Pargyline may increase the hypotensive activities of Cicletanine.	Approved
Penbutolol	Penbutolol may increase the hypotensive activities of Cicletanine.	Approved, Investigational
Pentazocine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Cicletanine.	Approved, Vet Approved
Pentolinium	Pentolinium may increase the hypotensive activities of Cicletanine.	Approved
Pentoxifylline	Pentoxifylline may increase the hypotensive activities of Cicletanine.	Approved, Investigational
Perindopril	Perindopril may increase the hypotensive activities of Cicletanine.	Approved
Pethidine	The risk or severity of adverse effects can be increased when Pethidine is combined with Cicletanine.	Approved
Phenazocine	The risk or severity of adverse effects can be increased when Phenazocine is combined with Cicletanine.	Experimental
Phenelzine	Phenelzine may increase the hypotensive activities of Cicletanine.	Approved
Pheniprazine	Pheniprazine may increase the hypotensive activities of Cicletanine.	Withdrawn
Phenoperidine	The risk or severity of adverse effects can be increased when Phenoperidine is combined with Cicletanine.	Experimental
Phenoxybenzamine	Phenoxybenzamine may increase the hypotensive activities of Cicletanine.	Approved
Phenoxypropazine	Phenoxypropazine may increase the hypotensive activities of Cicletanine.	Withdrawn
Phentolamine	Phentolamine may increase the hypotensive activities of Cicletanine.	Approved
Pinacidil	Pinacidil may increase the hypotensive activities of Cicletanine.	Withdrawn
Pindolol	Pindolol may increase the hypotensive activities of Cicletanine.	Approved
Piritramide	The risk or severity of adverse effects can be increased when Piritramide is combined with Cicletanine.	Investigational
Pirlindole	Pirlindole may increase the hypotensive activities of Cicletanine.	Approved
Pivhydrazine	Pivhydrazine may increase the hypotensive activities of Cicletanine.	Withdrawn
Polythiazide	Polythiazide may increase the hypotensive activities of Cicletanine.	Approved
Prazosin	Prazosin may increase the hypotensive activities of Cicletanine.	Approved
Propranolol	Propranolol may increase the hypotensive activities of Cicletanine.	Approved, Investigational
Quinapril	Quinapril may increase the hypotensive activities of Cicletanine.	Approved, Investigational
Quinine	Quinine may increase the hypotensive activities of Cicletanine.	Approved
Ramipril	Ramipril may increase the hypotensive activities of Cicletanine.	Approved
Rasagiline	Rasagiline may increase the hypotensive activities of Cicletanine.	Approved
Remifentanil	The risk or severity of adverse effects can be increased when Remifentanil is combined with Cicletanine.	Approved
Remikiren	Remikiren may increase the hypotensive activities of Cicletanine.	Approved
Rescinnamine	Cicletanine may increase the hypotensive activities of Rescinnamine.	Approved
Reserpine	Reserpine may increase the hypotensive activities of Cicletanine.	Approved
Rilmenidine	Rilmenidine may increase the hypotensive activities of Cicletanine.	Investigational
Riociguat	Cicletanine may increase the hypotensive activities of Riociguat.	Approved
Rituximab	Cicletanine may increase the hypotensive activities of Rituximab.	Approved
Safrazine	Safrazine may increase the hypotensive activities of Cicletanine.	Withdrawn
Saprisartan	Saprisartan may increase the hypotensive activities of Cicletanine.	Experimental
Selegiline	Selegiline may increase the hypotensive activities of Cicletanine.	Approved, Investigational, Vet Approved
Selexipag	Selexipag may increase the hypotensive activities of Cicletanine.	Approved
Sildenafil	Sildenafil may increase the antihypertensive activities of Cicletanine.	Approved, Investigational
Sitaxentan	Cicletanine may increase the hypotensive activities of Sitaxentan.	Approved, Investigational, Withdrawn
Sodium phosphate	Cicletanine may increase the nephrotoxic activities of Sodium phosphate.	Approved
Spirapril	Spirapril may increase the hypotensive activities of Cicletanine.	Approved
Sufentanil	The risk or severity of adverse effects can be increased when Sufentanil is combined with Cicletanine.	Approved, Investigational
Tadalafil	Tadalafil may increase the antihypertensive activities of Cicletanine.	Approved, Investigational
Talinolol	Talinolol may increase the hypotensive activities of Cicletanine.	Investigational
Tapentadol	The risk or severity of adverse effects can be increased when Tapentadol is combined with Cicletanine.	Approved
Telmisartan	Telmisartan may increase the hypotensive activities of Cicletanine.	Approved, Investigational
Temocapril	Temocapril may increase the hypotensive activities of Cicletanine.	Experimental, Investigational
Terlipressin	Terlipressin may increase the hypotensive activities of Cicletanine.	Approved, Investigational
Tetrahydropalmatine	Tetrahydropalmatine may increase the hypotensive activities of Cicletanine.	Investigational
Theodrenaline	Cicletanine may increase the hypotensive activities of Theodrenaline.	Investigational
Tibolone	Tibolone may increase the hypotensive activities of Cicletanine.	Approved
Ticrynafen	Ticrynafen may increase the hypotensive activities of Cicletanine.	Withdrawn
Tilidine	The risk or severity of adverse effects can be increased when Tilidine is combined with Cicletanine.	Experimental
Timolol	Timolol may increase the hypotensive activities of Cicletanine.	Approved
Tolazoline	Tolazoline may increase the hypotensive activities of Cicletanine.	Approved, Vet Approved
Tolonidine	Cicletanine may increase the hypotensive activities of Tolonidine.	Experimental
Toloxatone	Toloxatone may increase the hypotensive activities of Cicletanine.	Approved
Torasemide	Torasemide may increase the hypotensive activities of Cicletanine.	Approved
Tramadol	The risk or severity of adverse effects can be increased when Tramadol is combined with Cicletanine.	Approved, Investigational
Trandolapril	Trandolapril may increase the hypotensive activities of Cicletanine.	Approved
Trans-2-Phenylcyclopropylamine	Trans-2-Phenylcyclopropylamine may increase the hypotensive activities of Cicletanine.	Experimental
Tranylcypromine	Tranylcypromine may increase the hypotensive activities of Cicletanine.	Approved
Travoprost	Travoprost may increase the hypotensive activities of Cicletanine.	Approved
Treprostinil	Treprostinil may increase the hypotensive activities of Cicletanine.	Approved, Investigational
Trichlormethiazide	Trichlormethiazide may increase the hypotensive activities of Cicletanine.	Approved, Vet Approved
Trimazosin	Trimazosin may increase the hypotensive activities of Cicletanine.	Experimental
Trimethaphan	Trimethaphan may increase the hypotensive activities of Cicletanine.	Approved
Udenafil	Udenafil may increase the antihypertensive activities of Cicletanine.	Approved, Investigational
Unoprostone	Unoprostone may increase the hypotensive activities of Cicletanine.	Approved
Urapidil	Urapidil may increase the hypotensive activities of Cicletanine.	Investigational
Valsartan	Valsartan may increase the hypotensive activities of Cicletanine.	Approved, Investigational
Vardenafil	Vardenafil may increase the antihypertensive activities of Cicletanine.	Approved
Vincamine	Cicletanine may increase the hypotensive activities of Vincamine.	Experimental
Vinpocetine	Vinpocetine may increase the hypotensive activities of Cicletanine.	Investigational
Xipamide	Cicletanine may increase the hypotensive activities of Xipamide.	Experimental
Xylometazoline	Xylometazoline may increase the hypotensive activities of Cicletanine.	Approved
Yohimbine	Yohimbine may decrease the antihypertensive activities of Cicletanine.	Approved, Vet Approved
Zofenopril	Cicletanine may increase the hypotensive activities of Zofenopril.	Experimental

Food Interactions

Not Available

References

General References

Not Available

External Links

ChemSpider

49583

ChEBI

135078

ChEMBL

CHEMBL191886

ATC Codes

C03BX03 — Cicletanine

• C03BX — Other low-ceiling diuretics
• C03B — LOW-CEILING DIURETICS, EXCL. THIAZIDES
• C03 — DIURETICS
• C — CARDIOVASCULAR SYSTEM

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count
1, 2	Not Yet Recruiting	Treatment	Arterial Hypertension / Diabetes / Hypokalaemia / Hyponatremias	1
2	Terminated	Treatment	Pulmonary Arterial Hypertension (PAH)	1

Pharmacoeconomics

Manufacturers

Not Available

Packagers

Not Available

Dosage forms

Not Available

Prices

Not Available

Patents

Not Available

Properties

State

Not Available

Experimental Properties

Not Available

Predicted Properties

Property	Value	Source
Water Solubility	0.727 mg/mL	ALOGPS
logP	2.8	ALOGPS
logP	2.6	ChemAxon
logS	-2.6	ALOGPS
pKa (Strongest Acidic)	8.57	ChemAxon
pKa (Strongest Basic)	5.51	ChemAxon
Physiological Charge	0	ChemAxon
Hydrogen Acceptor Count	3	ChemAxon
Hydrogen Donor Count	1	ChemAxon
Polar Surface Area	42.35 Å2	ChemAxon
Rotatable Bond Count	1	ChemAxon
Refractivity	69.68 m3·mol-1	ChemAxon
Polarizability	26.49 Å3	ChemAxon
Number of Rings	3	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	Yes	ChemAxon
Veber's Rule	No	ChemAxon
MDDR-like Rule	No	ChemAxon

Predicted ADMET features

Not Available

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted GC-MS Spectrum - GC-MS	Predicted GC-MS	Not Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	Not Available

Taxonomy

Description

This compound belongs to the class of organic compounds known as chlorobenzenes. These are compounds containing one or more chlorine atoms attached to a benzene moiety.

Kingdom

Organic compounds

Super Class

Benzenoids

Class

Benzene and substituted derivatives

Sub Class

Halobenzenes

Direct Parent

Chlorobenzenes

Alternative Parents

Methylpyridines / Hydroxypyridines / Aryl chlorides / Heteroaromatic compounds / Oxacyclic compounds / Dialkyl ethers / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds / OrganochloridesHydrocarbon derivatives

show 1 more

Substituents

Chlorobenzene / Methylpyridine / Hydroxypyridine / Aryl chloride / Aryl halide / Pyridine / Heteroaromatic compound / Dialkyl ether / Ether / Organoheterocyclic compoundAzacycle / Oxacycle / Organonitrogen compound / Organochloride / Organohalogen compound / Organic nitrogen compound / Organooxygen compound / Hydrocarbon derivative / Organic oxygen compound / Organopnictogen compound / Aromatic heteropolycyclic compound

show 11 more

Molecular Framework

Aromatic heteropolycyclic compounds

External Descriptors

Not Available

Drug created on October 20, 2016 18:05 / Updated on September 01, 2017 12:24